Opening subject page...
Loading your content
Understanding the spectrum of myocardial ischemia from unstable angina to STEMI in the prehospital setting.
Coronary artery disease has been the leading cause of death worldwide for over a century, yet our understanding of the acute events that precipitate sudden cardiac death has evolved dramatically. The concept of acute coronary syndromes (ACS) emerged gradually as clinicians recognized that chest pain, electrocardiographic changes, and myocardial necrosis represented a continuum of ischemic injury rather than isolated disease entities. Before the modern era, physicians had limited tools to differentiate between reversible ischemia and irreversible infarction, and prehospital treatment was essentially nonexistent. The progression from bedside observation to 12-lead ECG interpretation and targeted pharmacotherapy in the field represents one of the most significant advances in emergency cardiovascular care.
This historical arc reveals a central question for the modern AEMT: how can prehospital providers rapidly distinguish among the types of ACS, initiate time-critical interventions, and communicate findings to receiving facilities in a way that maximizes myocardial salvage? The answer lies in understanding the shared pathophysiology of coronary plaque rupture and the clinical features that place each patient on the ACS spectrum.
Acute coronary syndromes encompass a spectrum of clinical presentations caused by the abrupt reduction of coronary blood flow to the myocardium. The underlying mechanism in the vast majority of cases is the rupture or erosion of an atherosclerotic plaque within a coronary artery, triggering platelet aggregation and thrombus formation that partially or completely occludes the vessel lumen. The degree and duration of occlusion determine whether the patient experiences transient ischemia without myocardial necrosis (unstable angina), subendocardial injury with biomarker elevation (NSTEMI), or transmural infarction with characteristic ECG changes (STEMI). Recognizing where a patient falls on this continuum is critical because time-to-treatment directly correlates with the volume of viable myocardium that can be preserved.
As depicted in the diagram above, all three ACS presentations share a common pathological origin—the disrupted atherosclerotic plaque—but differ in the extent and persistence of coronary occlusion. In unstable angina, a non-occlusive thrombus forms over the ruptured plaque, transiently reducing myocardial perfusion but not causing cellular death. With NSTEMI, the thrombus is larger or more persistent, leading to subendocardial necrosis detectable through elevated cardiac troponin levels. In STEMI, complete thrombotic occlusion produces transmural ischemia that manifests as ST-segment elevation on the 12-lead ECG. For the AEMT, the visual distinction between these presentations guides both the urgency of transport and the activation of downstream resources such as the cardiac catheterization laboratory.
The pathophysiology of ACS follows a well-characterized cascade that begins years before the acute event. Endothelial injury from risk factors such as hypertension, diabetes, smoking, and hyperlipidemia promotes the infiltration of low-density lipoproteins (LDL) into the arterial intima. Over time, macrophages engulf oxidized LDL to become foam cells, which accumulate to form a fatty streak. A fibrous cap composed of smooth muscle cells and collagen forms over the lipid core, creating the mature atherosclerotic plaque. The critical event in ACS occurs when this fibrous cap thins, fractures, or erodes, exposing highly thrombogenic subendothelial material to circulating platelets.
Upon plaque rupture, exposed collagen and tissue factor activate the intrinsic and extrinsic coagulation pathways simultaneously. Platelets adhere to the disrupted endothelium via glycoprotein Ib receptors binding to von Willebrand factor, then activate and release thromboxane A2 (TXA2) and adenosine diphosphate (ADP), which recruit additional platelets. Aspirin exerts its therapeutic effect by irreversibly inhibiting cyclooxygenase-1 (COX-1), blocking TXA2 synthesis and reducing further platelet aggregation. This is precisely why early aspirin administration is among the most important prehospital interventions in suspected ACS.
Myocardial ischemia fundamentally results from a mismatch between myocardial oxygen supply and demand. Oxygen supply depends on coronary blood flow (determined by perfusion pressure and coronary artery patency) and arterial oxygen content. Oxygen demand is driven by heart rate, contractility, wall tension (afterload), and preload. In ACS, supply is acutely reduced by the obstructing thrombus. Simultaneously, the stress response triggers catecholamine release that increases heart rate and contractility, paradoxically raising demand even as supply falls. This is why nitroglycerin—which dilates coronary arteries and reduces preload—can provide symptomatic relief by favorably shifting the supply–demand balance.
Differentiating among the three ACS presentations in the prehospital setting requires the integration of clinical history, symptom patterns, and—when available—12-lead ECG findings. While definitive differentiation between unstable angina and NSTEMI requires laboratory biomarker analysis that is beyond the AEMT scope, certain presentation features can help guide clinical decision-making and transport priority.
| Feature | Unstable Angina | NSTEMI | STEMI |
|---|---|---|---|
| Chest Pain Character | Substernal pressure/squeezing, often at rest or with minimal exertion; new onset or worsening pattern | Similar to UA, may be more severe or prolonged (> 20 min); often unrelieved by rest | Severe, crushing substernal pain; classically described as "elephant sitting on chest"; often with diaphoresis |
| Radiation | Left arm, jaw, neck, back, epigastrium | Same distribution as UA | Same distribution; bilateral arm radiation increases specificity |
| Associated Symptoms | Dyspnea, nausea, anxiety | Dyspnea, nausea, diaphoresis, weakness | Diaphoresis, nausea/vomiting, sense of impending doom, syncope |
| 12-Lead ECG | May be normal; ST depression; T-wave inversion | ST depression; T-wave inversion or flattening; may be non-diagnostic | ST elevation ≥ 1 mm in ≥ 2 contiguous leads; new LBBB may be equivalent |
| Cardiac Biomarkers | Troponin: Normal | Troponin: Elevated | Troponin: Elevated (often markedly) |
| Coronary Occlusion | Partial, transient | Near-total or intermittent total | Complete, persistent |
| Prehospital Priority | High — treat as ACS until ruled out | High — cannot distinguish from UA without troponin | HIGHEST — activate cath lab from field |
A significant proportion of ACS patients—particularly women, elderly patients, and those with diabetes—present with atypical symptoms that may not include classic substernal chest pain. These patients may report isolated dyspnea, generalized weakness, syncope, epigastric discomfort mistaken for indigestion, or diffuse upper body pain without a clear cardiac quality. Diabetic patients with autonomic neuropathy may experience silent ischemia—myocardial ischemia without perceivable pain. The AEMT must maintain a high index of suspicion for ACS in any patient with relevant risk factors even when the presentation seems benign, because missing an ACS diagnosis in these populations carries significant morbidity and mortality.
Consider the following clinical scenario that an AEMT might encounter during a 911 response. We will walk through the systematic assessment and management steps that align with current AHA and NAEMSP guidelines.
The pharmacological toolkit available to the AEMT for ACS management is focused but powerful. Understanding not only the indications but also the contraindications and potential complications of each medication is essential for safe patient care. The two cornerstone medications—aspirin and nitroglycerin—address different aspects of the ACS pathophysiology and are complementary rather than redundant.
| Parameter | Aspirin (ASA) | Nitroglycerin (NTG) |
|---|---|---|
| Mechanism | Irreversibly inhibits COX-1 → blocks TXA₂ → decreases platelet aggregation | Releases nitric oxide → smooth muscle relaxation → vasodilation (venous > arterial > coronary) |
| Dose | 324 mg chewable PO (four 81 mg tablets) | 0.4 mg (400 mcg) SL; may repeat × 3 doses at 3–5 min intervals |
| Onset of Action | ≈ 5 minutes (chewed); 30 min (swallowed) | 1–3 minutes SL |
| Contraindications | True aspirin allergy, active GI bleeding, recent hemorrhagic stroke | SBP < 90 mmHg, HR < 50 or > 100 (relative), phosphodiesterase inhibitor use (sildenafil within 24 hr, tadalafil within 48 hr), suspected right ventricular infarction |
| Key Side Effects | GI upset, bleeding risk (minor in single-dose prehospital context) | Hypotension, headache, reflex tachycardia |
| Primary Benefit | Reduces mortality by 23% when given early in ACS (ISIS-2 trial) | Symptom relief via preload reduction and coronary vasodilation |
The AEMT's management of ACS represents the critical first link in a chain of increasingly sophisticated interventions. Understanding where your care fits within the broader treatment continuum helps you communicate more effectively with receiving facilities and appreciate why each prehospital action matters. As you advance in your career—potentially to the paramedic level—you will gain access to additional pharmacological and procedural tools that build upon the foundation covered in this lesson.
| Intervention Domain | AEMT Level | Paramedic / Hospital Level |
|---|---|---|
| ECG Interpretation | Acquire 12-lead; identify STEMI by ST elevation criteria; transmit to receiving facility | Advanced rhythm interpretation; identification of STEMI equivalents (de Winter, Wellens); serial ECGs |
| Antiplatelet Therapy | Aspirin 324 mg chewable | Aspirin + P2Y₁₂ inhibitor (clopidogrel, ticagrelor); GP IIb/IIIa inhibitors in cath lab |
| Anti-Ischemic Therapy | Nitroglycerin SL | NTG drip (IV); morphine for refractory pain; beta-blockers; heparin/enoxaparin |
| Reperfusion | Cath lab activation from field; minimize scene time; bypass to PCI center | Fibrinolytics (when PCI not available within 120 min); primary PCI with stent placement |
| Dysrhythmia Management | Monitor; defibrillation for VF/pulseless VT; basic CPR | Antiarrhythmics (amiodarone, lidocaine); synchronized cardioversion; transcutaneous pacing |
The concept of first medical contact (FMC) to device time underscores why the AEMT's role is so consequential. Current AHA guidelines recommend that STEMI patients undergo percutaneous coronary intervention (PCI) within 120 minutes of first medical contact—or 90 minutes from hospital arrival (door-to-balloon). Every minute the AEMT saves through efficient assessment, early ECG acquisition, and prehospital cath lab activation directly translates to preserved myocardium. Studies demonstrate that each 30-minute delay in reperfusion is associated with a measurable increase in one-year mortality. This temporal relationship reinforces the axiom that in ACS care, time is myocardium.
Acute coronary syndromes represent a continuum of myocardial ischemic events caused by atherosclerotic plaque rupture and subsequent coronary thrombosis. The spectrum ranges from unstable angina (transient ischemia, no necrosis, normal troponin) through NSTEMI (subendocardial necrosis, elevated troponin, no ST elevation) to STEMI (transmural infarction, elevated troponin, ST elevation on 12-lead ECG). The degree of coronary occlusion—partial versus complete—determines presentation severity and guides the urgency of definitive treatment.
The AEMT plays a pivotal role by performing rapid assessment, acquiring a 12-lead ECG to identify STEMI, administering aspirin 324 mg (chewed) to inhibit platelet aggregation, carefully administering nitroglycerin 0.4 mg SL for symptom relief (while watching for right ventricular infarction contraindications), establishing IV access, and initiating cath lab activation for STEMI patients—all while maintaining continuous cardiac monitoring and preparing for potential cardiac arrest. Remember that atypical presentations (especially in women, elderly, and diabetic patients) require a high index of suspicion, and the guiding principle of ACS care is that time is myocardium—every minute of delay in reperfusion means more irreversible cardiac damage.